1.02 -0.01 (-0.97%)
After hours: 5:53PM EST
|Bid||1.01 x 800|
|Ask||1.02 x 1000|
|Day's Range||1.0300 - 1.1000|
|52 Week Range||0.8100 - 12.8000|
|Beta (3Y Monthly)||2.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.75|
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, announced today the initiation of a Phase II study to evaluate PTI-125 as a potential first line treatment in patients with Alzheimer’s disease. This clinical study is supported by a research grant award from the National Institute on Aging (NIA), the primary Federal agency supporting new research in Alzheimer’s disease. “There is a profound and timely need to develop new drugs for Alzheimer’s,” said Remi Barbier, President & CEO.
Every investor in Pain Therapeutics Inc (NASDAQ:PTIE) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders Read More...
Pain Therapeutics Inc. shares surged as much as 18% before evening out to a 7.8% increase in Monday premarket trade after the company said it is challenging the U.S. Food and Drug Administration's August decision to not approve its abuse-deterrent opioid medication Remoxy. Pain Therapeutics and the FDA plan to meet in person on Jan. 31, the company said. Remoxy is a form of the opioid oxycodone that comes in a "thick, sticky, high viscosity gel formulation" that is supposed to deter abuse, including "syringe-ability, injection, and rapid extraction in ingestible solvents," according to Pain Therapeutics. The FDA has encouraged the development of these types of opioid formulations, with the hope that they will help fight the U.S.'s opioid crisis, but there is evidence that these products can still be abused. When the FDA failed to approve Remoxy in early August, it said that the drug application package did not show that Remoxy's benefits outweigh its risks. Pain Therapeutics said on Monday, though, that the FDA had made errors during a June advisory committee meeting, and implied that the FDA's review of its product was biased. The biopharmaceutical company's challenge comes as another new opioid formulation was approved earlier this month over significant controversy about whether it could be abused, and the FDA has said it may need to reconsider how it approves new opioids. Pain Therapeutics shares have lifted 1.8% over the last three months to $1.15, compared with a 1.8% drop in the S&P 500 .
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, announced today it will release third quarter 2018 financial results, and hold a conference call with a Q&A session, on Monday, October 29, 2018 at 4:30 p.m. Eastern Time. The Company’s conference call can be accessed by dialing toll-free (877) 407-4018 (or 201 689-8471 for international callers). A replay will be available toll-free at (844) 512-2921, (or 412 317-6671 for international callers), using the conference ID code 13684539. To listen to the Company’s webcast, please go to http://www.paintrials.com/ and click on “News”, then “Event & Presentations” to register. You may access http://www.paintrials.com/ at any time through Monday, November 5th, 2018, for a replay of the webcast for this conference call.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that Mr. Eric Schoen will join its management team as Chief Financial Officer, effective on or before November 7, 2018. Mr. Schoen joins the Company with over 19 years of finance experience with growth companies. Most recently, he was SVP, Finance & Chief Accounting Officer of Vermillion, Inc., a publicly-traded healthcare company. Mr. Schoen also spent nine years with PricewaterhouseCoopers in the assurance, transaction services and global capital markets groups.
shed 53% to $1.35 on Thursday, Oct. 4, after the company said it was filing an "administrative appeal" with the Federal Drug Administration after the agency rejected a drug the company was developing. In August, the FDA rejected Pain Therapeutics' Remoxy drug, an oxycodone designed to discourage most methods of tampering linked to opioid abuse, because the benefits of the drug weren't great enough to justify the risks. The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, part of the FDA, voted 14 to 3 against the drug.
DYAI has over $40 million in the bank, a stock buyback agreement, and entered into an additional fully funded research collaboration with Sanofi-Aventis to test the feasibility of using C1 to produce multiple genes for vaccine and drug applications. For those that do not know Sanofi-Aventis is over a $100 Billion company that trades on the New York Stock Exchange. DYAI currently has assets on its balance sheet of over $49 Million while only has a market cap of $46 Million.
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Both Pain Therapeutics and VistaGen Therapeutics were two biotech stocks seeing big gains on Wednesday. While Pain Therapeutics had no news to explain a 200% ...
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that it has been awarded an approximately $3.5 million research grant from the National Institutes of Health (NIH) to support a Phase II program with PTI-125, the Company’s drug candidate to treat Alzheimer’s disease. The NIH's National Institute on Aging awarded the Company this clinical research grant following an in-depth, peer-reviewed evaluation of PTI-125 for scientific and technical merit. The NIH grant award will enable the Company to conduct clinical tests of PTI-125 in patients with Alzheimer’s disease. In Q4 2018, the Company expects to initiate a Phase II study in Alzheimer’s patients using PTI-125. In mid-2019, the Company expects to initiate a second Phase II study in Alzheimer’s patients using PTI-125.
Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, today announced that it will host a live conference call to provide a strategic update regarding its business, its science and its pipeline. The call is scheduled to be held Thursday, October 4th at 10 AM Eastern time, 9 AM Central time. The Company’s presentation will be available live via webcast and conference call. To listen to the webcast and view the accompanying slide presentation, please go to the Company’s website at http://www.paintrials.com/ and click on the webcast icon at least 15 minutes before the presentation is to begin to register. If you are unable to listen to the live webcast, please access http://www.paintrials.com/ at any time within seven days to listen to a replay of the webcast.
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Shares of Tesla dropped on Wednesday as traders learned that the company has been hit with a subpoena by the SEC regarding CEO Elon Musk's tweet about considering to take the company private and having funding secured. Shares of Pain Therapeutics were skyrocketing on news that the company has received an Alzheimer's grant. Pain Therapeutics, Inc. shares closed up nearly 77% yesterday on about 18.8 million shares traded.
Pain Therapeutics notes that the grant is for a total of $3.20 million. PTI-125 is a new drug that Pain Therapeutics is developing to treat Alzheimer’s disease. The drug is a molecule that has the potential to treat Alzheimer’s disease.
The FDA rejected Pain’s lead asset and said the drug’s negatives outweigh its positives. "This is a bizarre conclusion to reach, especially during a time of staggering human and economic toll created by opioid abuse and addiction," Pain Therapeutics CEO Remi Barbier said in a statement. Pain Therapeutics said it will redirect its resources to advance its Alzheimer’s assets.